In June 2024 it was announced that CTIBIOTECH has launched the SAFESKIN3D project to produce flexible 3D bioprinted human skin models for use in the evaluation of vaccines, particularly next generation mRNA vaccines. CTIBIOTECH has secured a strategic partnership with Sanofi, who will act as “beta tester”, providing “expert feedback” to validate and refine the models.
SAFESKIN3D
The project is described as a “significant technological breakthrough” for vaccine development. It leverages CTIBIOTECH’s expertise in 3D printing and human tissue engineering to create advanced models that mimic subcutaneous and intramuscular injection sites. This will provide pharmaceutical companies with the opportunity to predict the effects of mRNA vaccines, reducing reliance on animal testing.
The SAFESKIN3D project seeks to:
- Develop sophisticated 3D human skin models including epidermis, dermis, hypodermis, and muscle layers
- Integrate immune cells, sensory neurons, and vascular components to provide a comprehensive vaccine safety testing model
- Reduce vaccine development cost and time
- Minimise the need for animal experimentation
CTIBIOTECH is investing €1 million in the project, supported by €500,000 from:
- Sanofi iDEA-TECH Award
- Transforming SMEs through innovation | France 2030 award
- Important Project of Common European Interest (IPCEI Med4Cure award)
Professor Colin McGuckin, President and Chief Innovation Officer at CTIBIOTECH, described the project as a “testament to our commitment to innovation and excellence in making human tissues”.
“By developing advanced 3D bioprinted skin models, we not only enhance the safety and efficacy of new vaccines but also pave the way for more ethical and sustainable research practices. This project will significantly reduce the reliance on animal testing and accelerate the development of next-generation vaccines, ultimately benefitting public health at a global scale.”
Professor McGuckin is “thrilled” to work with Sanofi and “leverage their expertise to bring this transformative technology to market”. Dr Nicolas Forraz, Chief Executive Officer of CTIBIOTECH, believes the launch is a “pivotal moment” for the organisation and the “broader field of vaccine development”.
“Our innovative 3D bioprinted skin models will provide a more accurate and ethical method for assessing vaccine safety, ultimately leading to faster and more cost-effective development of new vaccines.”
The project demonstrates Dr Forraz’s team’s “commitment to scientific excellence” and “dedication to transforming public health”.
For more on innovative vaccine technologies, don’t forget to get your tickets to the Congress in Barcelona here and subscribe to our weekly updates here.
